Neuland Labs.
Neuland Labs. Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
The short version
Neuland aims for approximately 20% growth annually over FY27 and FY28. Neuland expects FY27 and FY28 to be years of growth, with aspirations to grow around 20% annually.
From Neuland Labs.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Neuland aims for approximately 20% growth annually over FY27 and FY28.
- FY27 is expected to be a good year with growth, though lumpiness and volatility due to a few key molecules will persist.
- Commercial CMS growth is primarily driven by a handful of active molecules, with new projects adding diversity.
- Development revenue is anticipated to increase in FY27 with new projects lined up, contributing to future commercial revenue beyond FY27.
- Peptide manufacturing capabilities are expanding with a new facility being commissioned soon, already having order visibility and readiness for projects.
- The company is investing significantly (~INR 203 crores capex in Q1 FY27) in capacity expansions and strategic growth initiatives.
- Long-term growth beyond 3-5 years depends on new molecules from a healthy and improving development pipeline expected to replenish and surpass current commercial product base.
Profitability & Margins
See what Neuland Labs. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Neuland has been investing at a higher pace and scale over the last 3 years, continuing into FY27, focusing on manufacturing infrastructure, R&D, peptides, sterile APIs, and capacity expansion.
- Recent capital expenditure in Q1FY27 was INR121.6 crores, mainly for new R&D and peptide facilities.
- Capital investments of approx. INR203 crores were approved in the quarter, with INR196 crores earmarked for strategic growth, largely capacity expansion at Unit 1.
- Total approved capex over 13 quarters is INR1,460 crores, with INR870 crores spent to date; the remainder is committed toward ongoing projects.
- Future capex will be significantly higher in quantum compared to past investments and will qualitatively differ by targeting newer, more complex modalities and potential geographic diversification.
- Plans may include organic or M&A-driven overseas investments to support growth beyond 3-4 years.
- Strategic collaborations, such as with Gland Pharma, underpin their focus on specialty and sterile APIs.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Neuland Labs. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Neuland Laboratories Limited typically has good visibility of at least a 6-month order book as a CDMO.
- The company is cautious about fully revealing exact order book details or expected yearly performance.
- They aspire to achieve about 20% growth over FY27 and FY28 but avoid giving firm guidance.
- As per Saharsh Davuluri, order visibility is consistent with expectations and factors in any destocking or stocking risks.
- No abrupt surprises from destocking are expected during FY27.
- The peptide manufacturing plant has projects lined up even before commissioning, indicating good order visibility for this new facility.
- Overall, the company maintains a well-balanced and visible order book supporting steady growth and cautious optimism.
Neuland Labs. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹776 Cr, net profit ₹213 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Neuland Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Neuland Labs. Q1 FY27 results?
Neuland aims for approximately 20% growth annually over FY27 and FY28. Neuland expects FY27 and FY28 to be years of growth, with aspirations to grow around 20% annually.
What is Neuland Labs. share price analysis?
Neuland Labs. currently shows a neutral. The stock trades at a P/E of 60.1 with a market cap of ₹29,895 Cr. Investors should review the full earnings analysis for detailed insights.
Is Neuland Labs. planning capital expenditure?
Neuland has been investing at a higher pace and scale over the last 3 years, continuing into FY27, focusing on manufacturing infrastructure, R&D, peptides, sterile APIs, and capacity expansion. - Recent capital expenditure in Q1FY27 was INR121.6 crores, mainly for new R&D and peptide facilities. - Capital investments of approx.
Keep Neuland Labs. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.